We are live on
!
Find out more
HSA
Hussman Strategic Advisors Portfolio holdings
AUM
$463M
1-Year Est. Return
16%
This Fund
S&P 500
This Quarter
Est. Return
+4.35%
1 Year Est. Return
+16%
3 Year Est. Return
+35.45%
5 Year Est. Return
+32.62%
10 Year Est. Return
+255.18%
AUM
$372M
AUM Growth
+$10.5M
(+2.9%)
Cap. Flow
+$3.66M
Cap. Flow
% of AUM
0.99%
Top 10 Holdings %
Top 10 Hldgs %
17.28%
Holding
264
New
49
Increased
26
Reduced
48
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fastenal
FAST
|
+$3.95M |
| 2 |
Generac Holdings
GNRC
|
+$3.69M |
| 3 |
Xylem
XYL
|
+$3.63M |
| 4 |
C.H. Robinson
CHRW
|
+$3.57M |
| 5 |
Amneal Pharmaceuticals
AMRX
|
+$3.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$3.89M |
| 2 |
Pilgrim's Pride
PPC
|
+$3.75M |
| 3 |
Colgate-Palmolive
CL
|
+$3.58M |
| 4 |
Wabash National
WNC
|
+$3.19M |
| 5 |
Usana Health Sciences
USNA
|
+$3.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.62% |
| 2 | Technology | 16.03% |
| 3 | Consumer Discretionary | 15.97% |
| 4 | Materials | 12.67% |
| 5 | Industrials | 11.3% |
Similar funds
CPIM
SHWM
CWWM
SWMG
NG
PC
AC
PRCP
Hussman Strategic Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Hussman Strategic Advisors held 264 positions worth $372M, up 2.9% from $361M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Hussman Strategic Advisors's Q2 2018 filing shows 49 new, 26 increased, 48 reduced and 45 closed positions. Its largest new stake was Fastenal: 304,800 shares worth $3.67M. The largest sale was Impax Laboratories, Inc., an estimated $3.89M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 17% a quarter earlier, followed by Technology and Consumer Discretionary.
- Hussman Strategic Advisors's largest Q2 2018 buy was Fastenal: 304,800 shares worth $3.67M.
- Hussman Strategic Advisors added most to C.H. Robinson in Q2 2018, an estimated $3.57M increase.
- Hussman Strategic Advisors's biggest Q2 2018 reduction was Varian Medical Systems, Inc., cutting an estimated $2.99M.
- Hussman Strategic Advisors fully exited Impax Laboratories, Inc. in Q2 2018, selling an estimated $3.89M.
- Hussman Strategic Advisors's ten largest holdings make up 17% of its $372M portfolio in Q2 2018.
- Hussman Strategic Advisors opened 49 new positions and closed 45 in Q2 2018.
- Hussman Strategic Advisors's portfolio value rose 2.9% quarter-over-quarter to $372M.
Based on Hussman Strategic Advisors's 13F filing for Q2 2018, filed 31 Jul 2018.